Jannah Theme License is not validated, Go to the theme options page to validate the license, You need a single license for each domain name.
Business

Titan Medical Announces Publication of Patent Application, Expands Commitment to Continued Innovation in Single-Access Robotic-Assisted Surgery, Canadian Business Journal

TORONTO, Sept. 22, 2022 (GLOBE NEWSWIRE) — Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD) develops and commercializes an innovative surgical technology for single-access, robotic-assisted surgery (RAS) is a medical device company focused on today announced the publication of International Patent Application No. PCT/CA2022/050392. It is intended for acquisition in the United States and other major markets under the Patent Cooperation Treaty (PCT).

This patent application generally describes a RAS system designed to provide a broader robust workspace field of view than provided by conventional endoscopic techniques designed to capture only a portion of the surgical site. Discloses a dexterous endoscopic technique for use in the. The technology described in the patent application can be utilized in a variety of single-access RAS systems, including one designed to support three instruments that can be placed simultaneously within the insertion conduit.

Cary Vance says: , President and CEO of Titan. “While we are focused on the development, clinical and regulatory activities of the Enos system, we are committed to continuing to improve the surgical experience for patients, surgeons and hospitals through research and development of RAS technology components and systems. Filing patents on our inventions is an important step in protecting the value we continue to create, including those designed for the next generation of technologies and systems.Innovating and developing our RAS technology roadmap further. As we move forward, we look forward to positioning Titan in a competitive position, particularly with respect to future RAS entrants, and extending our leadership in single-access innovation and intellectual property.”

Titan has over 220 units covering the US and other jurisdictions that support and cover various aspects of single-access RAS, including Enos system surgeon workstations, patient carts, dexterous joint instruments, and ergonomic hands. We have developed an extensive intellectual property portfolio with over 100,000 patents pending and issued. Controller, enhanced vision system, advanced control software, and an intuitive surgeon overlay that provides intraoperative feedback. This cover of single-access RAS, and of the Enos system in particular, along with a cover of more general aspects of the RAS technology, further protects the RAS technology and gives the company multiple intellectual property options, including the possibility of further licensing the technology. may provide. Assistance in securing competitive commercial channels.

About Titan Medical

Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD) is a medical device company headquartered in Toronto, Ontario with operations in Chapel Hill, North Carolina that uses innovative technology through a single access point. focused on enhancing robotic-assisted surgery (RAS) in The Enos™ Robotic Single Access Surgical System has been developed with a focus on ergonomics to provide a surgical experience that mimics the real-world movements demanded by the surgeon, allowing the surgeon to extend range of motion in confined spaces. It features an articulated instrument designed to Dexterity and the ability to exert force necessary to complete common surgical tasks. With the Enos system, Titan will initially pursue indications for gynecologic surgery.

Enos™ is a trademark of Titan Medical Inc.

For more information, please visit www.titanmedicalinc.com and follow us. @Titan Medical on Twitter and LinkedIn.

Forward-Looking Statements

This news release contains “forward-looking statements” within the meaning of applicable Canadian and US securities laws. It reflects management’s current expectations of the company’s future growth, operating results, performance and business prospects and opportunities. Forward-looking statements are, but not always, “may,” “could,” “may,” “will,” “expect,” “believe,” , “expects”, “intends”, etc. ”, “presumed”, “probable” and similar expressions. However, these words do not constitute all forward-looking statements. Forward-looking statements in this release may include, but are not limited to, references to the following: Company plans under the PCT. Potential benefits of the company’s technology, including dexterous endoscopic technology that provides a robust view of the workspace. The technology described in the patent application is utilized in various single access RAS systems. The company’s commitment to becoming an innovation leader in single-access RAS that includes but extends beyond the Enos system. The company’s commitment to improving the surgical experience for patients, surgeons and hospitals. The company’s expectations to extend its leadership in Single Access innovation and intellectual property. The company’s competitive position, including with respect to his future RAS entrants. The scope of the company’s intellectual property portfolio and the options offered. The Enos Robotic Single Access Surgical System has been developed with a focus on ergonomics to provide a surgical experience that mimics the real-life movements demanded by surgeons. Titan also intends to initially pursue gynecological surgical indications. These statements reflect management’s current views regarding future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions. Many factors may cause the actual results, performance or achievements of the Company to be expressed or implied by forward-looking statements, including but not limited to those set forth in “Risk Factors.” Future results, performance or achievements may differ materially. Sections of the Company’s Annual Report for the fiscal year ended December 31, 2021 are available at www.sedar.com and www.sec.gov. If one or more of these risks or uncertainties materializes or the assumptions underlying the forward-looking statements prove incorrect, the actual results, performance or achievements of this news release may differ. may differ materially from those expressed or implied by the forward-looking statements contained herein. These factors should be considered carefully and prospective investors should not place undue reliance on forward-looking statements. Forward-looking statements contained in news releases are based on what management currently believes to be reasonable assumptions, but actual results, performance or achievements may differ from those forward-looking statements. We cannot guarantee that future investors will agree. Except as required by law, we do not update or revise any forward-looking statements as a result of new information, future events or otherwise. expressly disclaims any intention or obligation to

contact
Kristen Galfetti
Vice President of Investor Relations
& Corporate Communications
+1-781-869-2553
[email protected]

###


CBJ Newsmaker



Titan Medical Announces Publication of Patent Application, Expands Commitment to Continued Innovation in Single-Access Robotic-Assisted Surgery, Canadian Business Journal

Source link Titan Medical Announces Publication of Patent Application, Expands Commitment to Continued Innovation in Single-Access Robotic-Assisted Surgery, Canadian Business Journal

Related Articles

Back to top button